WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Lantern Pharma Inc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Research
Vipergen ApS, Anavo Therapeutics | May 18, 2021
Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen'...
Cell and Gene Therapy, Industrial Impact
Evaxion | February 10, 2023
Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion...
MedTech, Industrial Impact
Globenewswire | April 13, 2023
Centogene N.V. the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options. Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially avai...
Aldevron | January 20, 2023
Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...
Cell and Gene Therapy
Whitepaper
Medical
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE